Advancing Therapies for Patients

Find a clinical trial


page image
shadow image

Text Size

minus image

plus image

plus image


Print image

Email a Friend


Find a clinical trial

COMBI-d study for patients with metastatic melanoma


COMBI-d: a phase III study on the combination of dabrafenib and trametinib in patients with metastatic melanoma

Dr Tobias-Hendrik Arkenau describes the results of the COMBI-d study: a randomised, double-blind, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. 

Latest Videos

watch the latest videos.

Learn more


news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals